# A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

> **NCT03714815** · PHASE2 · TERMINATED · sponsor: **Actelion** · enrollment: 91 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

## Interventions

- **DRUG:** macitentan 10 mg

## Key facts

- **NCT ID:** NCT03714815
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-07
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** the absence of a positive trend in all efficacy parameters indicates that macitentan 10 mg does not have a beneficial effect in patients with HFpEF and PVD.
- **Last updated:** 2025-02-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03714815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03714815, "A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03714815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*